An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts
Bladder cancer (BLCA) is featured with high incidence and mortality. Whether the IFN-γ signaling could be used as an immunotherapy determinant for BLCA has not been fully confirmed. In this study, the transcriptome data and clinical information of BLCA samples were collected from The Cancer Genome A...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.1100317/full |
| _version_ | 1797961692999581696 |
|---|---|
| author | Hao Deng Hao Deng Dingshan Deng Dingshan Deng Tiezheng Qi Zhi Liu Zhi Liu Longxiang Wu Longxiang Wu Junbin Yuan Junbin Yuan |
| author_facet | Hao Deng Hao Deng Dingshan Deng Dingshan Deng Tiezheng Qi Zhi Liu Zhi Liu Longxiang Wu Longxiang Wu Junbin Yuan Junbin Yuan |
| author_sort | Hao Deng |
| collection | DOAJ |
| description | Bladder cancer (BLCA) is featured with high incidence and mortality. Whether the IFN-γ signaling could be used as an immunotherapy determinant for BLCA has not been fully confirmed. In this study, the transcriptome data and clinical information of BLCA samples were collected from The Cancer Genome Atlas (TCGA). Besides, four immunotherapy cohorts including IMvigor210 cohort, Gide cohort, Van Allen cohort, and Lauss cohort were collected. The Xiangya real-world cohort was used for independent validation. An IFN-γ-related signature was developed and validated in BLCA for predicting prognosis, mutation, tumor microenvironment status, and immunotherapy response. This is the first study focusing on the comprehensive evaluation of predictive values on the IFN-γ-related signature in BLCA. The potential clinical application of the IFN-γ-related signature was expected to be further validated with more prospective clinical cohorts. |
| first_indexed | 2024-04-11T01:01:43Z |
| format | Article |
| id | doaj.art-26628bc402b741e78bdf7ae67a83160a |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-11T01:01:43Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-26628bc402b741e78bdf7ae67a83160a2023-01-04T15:27:13ZengFrontiers Media S.A.Frontiers in Genetics1664-80212023-01-011310.3389/fgene.2022.11003171100317An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohortsHao Deng0Hao Deng1Dingshan Deng2Dingshan Deng3Tiezheng Qi4Zhi Liu5Zhi Liu6Longxiang Wu7Longxiang Wu8Junbin Yuan9Junbin Yuan10Department of Urology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Urology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaXiangya School of Medicine, Central South University, Changsha, ChinaDepartment of Urology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Urology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Urology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaBladder cancer (BLCA) is featured with high incidence and mortality. Whether the IFN-γ signaling could be used as an immunotherapy determinant for BLCA has not been fully confirmed. In this study, the transcriptome data and clinical information of BLCA samples were collected from The Cancer Genome Atlas (TCGA). Besides, four immunotherapy cohorts including IMvigor210 cohort, Gide cohort, Van Allen cohort, and Lauss cohort were collected. The Xiangya real-world cohort was used for independent validation. An IFN-γ-related signature was developed and validated in BLCA for predicting prognosis, mutation, tumor microenvironment status, and immunotherapy response. This is the first study focusing on the comprehensive evaluation of predictive values on the IFN-γ-related signature in BLCA. The potential clinical application of the IFN-γ-related signature was expected to be further validated with more prospective clinical cohorts.https://www.frontiersin.org/articles/10.3389/fgene.2022.1100317/fullbladder cancerimmunotherapyIFN-γprognosisreal-world cohort study |
| spellingShingle | Hao Deng Hao Deng Dingshan Deng Dingshan Deng Tiezheng Qi Zhi Liu Zhi Liu Longxiang Wu Longxiang Wu Junbin Yuan Junbin Yuan An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts Frontiers in Genetics bladder cancer immunotherapy IFN-γ prognosis real-world cohort study |
| title | An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts |
| title_full | An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts |
| title_fullStr | An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts |
| title_full_unstemmed | An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts |
| title_short | An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts |
| title_sort | ifn γ related signature predicts prognosis and immunotherapy response in bladder cancer results from real world cohorts |
| topic | bladder cancer immunotherapy IFN-γ prognosis real-world cohort study |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.1100317/full |
| work_keys_str_mv | AT haodeng anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT haodeng anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT dingshandeng anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT dingshandeng anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT tiezhengqi anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT zhiliu anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT zhiliu anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT longxiangwu anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT longxiangwu anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT junbinyuan anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT junbinyuan anifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT haodeng ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT haodeng ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT dingshandeng ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT dingshandeng ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT tiezhengqi ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT zhiliu ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT zhiliu ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT longxiangwu ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT longxiangwu ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT junbinyuan ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts AT junbinyuan ifngrelatedsignaturepredictsprognosisandimmunotherapyresponseinbladdercancerresultsfromrealworldcohorts |